

1 **Outbreak of severe community-acquired bacterial**
2 **infections from *Streptococcus pyogenes*, *Streptococcus***
3 ***pneumoniae*, *Neisseria meningitidis*, and *Haemophilus***
4 ***influenzae* among children in North Rhine-Westphalia**
5 **(Germany), October to December 2022**
6

7 Sarah C. Goretzki¹, MD, Mark van der Linden², PhD,
8 Andreas Itzek², PhD, Tom Hühne¹, MD, Roland O.
9 Adelman³, MD, Firas Ala Eldin⁴, MD, Mohamed
10 Albarouni⁵, MD, Jan-Claudius Becker⁶, MD, Michael A.
11 Berghäuser⁷, MD, Thomas Boesing⁸, MD, Michael
12 Boeswald⁹, MD, Milian Brasche¹⁰, MD, Francisco Brevis¹¹,
13 MD, Rokya Camara¹², MD, Clara Deibert¹³, MD, Frank
14 Dohle¹⁴, MD, Jörg Dolgner¹⁵, MD, Jan Dziobaka¹⁶, MD,
15 Frank Eifinger¹⁷, MD, Natalie Elting¹⁸, MD, Matthias
16 Endmann¹⁹, MD, Guido Engelmann²⁰, MD, Holger Frenzke²¹,
17 MD, Monika Gappa²², MD, Bahman Gharavi²³, MD,
18 Christine Goletz²⁴, MD, Eva Hahn²⁵, MD, Yvonne
19 Heidenreich²⁶, MD, Konrad Heimann¹⁰, MD, Kai O.
20 Hensel²⁷, MD, Hans-Georg Hoffmann²⁸, MD, Marc
21 Hoppenz²⁹, MD, Gerd Horneff³⁰, MD, Helene Klassen³¹,
22 MD, Cordula Körner-Rettberg³², MD, Alfred Längler³³, MD,
23 Pascal Lenz³⁴, MD, Klaus Lohmeier³⁵, MD, Andreas
24 Müller³⁶, MD, Frank Niemann³⁷, MD, Michael Paulussen³⁸,
25 MD, Falk Pentek³⁹, MD, Ruy Perez⁴⁰, MD, Markus Pingel⁴¹,
26 MD, Philip Repges⁴², MD, Tobias Rothoef⁴³, MD, Jochen
27 Rübo⁴⁴, MD, Herbert Schade⁴⁵, MD, Robert Schmitz⁴⁶, MD,
28 Peter Schonhoff⁴⁷, MD, Jan N. Schwade⁴⁸, MD, Tobias
29 Schwarz⁴⁹, MD, Peter Seiffert⁵⁰, MD, Georg Selzer⁵¹, MD,
30 Uwe Spille⁵², MD, Carsten Thiel⁵³, MD, Ansgar Thimm⁵⁴,
31 MD, Bartholomäus Urgatz⁵⁵, MD, Alijda van den Heuvel⁵⁶,
32 MD, Tan van Hop⁵⁷, MD, Verena Giesen⁵⁸, MD, Stefan
33 Wirth⁵⁹, MD, Thomas Wollbrink⁶⁰, MD, Daniel Wüller⁶¹,
34 MD, Ursula Felderhoff-Müser¹, MD, Christian Dohna-
35 Schwake¹, MD, Thiên-Trí Lâm⁶², PhD, Heike Claus⁶², PhD,
36 N. Bruns¹, MD
37

38 **Affiliations:** ¹Department of Pediatrics I (Neonatology, Pediatric Intensive Care, Pediatric
39 Neurology, and Pediatric Infectious Diseases), Department of Pediatrics, University
40 Hospital, Essen University of Duisburg-Essen, Essen, Germany; ²Department of Medical
41 Microbiology, German National Reference Centre for Streptococci, University Hospital
42 RWTH Aachen, Aachen, Germany; ³Department of General Pediatrics, Klinikum
43 Oberberg, Kreiskrankenhaus Gummersbach, Gummersbach, Germany; ⁴Department of
44 General Pediatrics, Helios Hospital Schwelm, Schwelm, Germany; ⁵Division of
45 Rheumatology, Department of General Pediatrics, Asklepios Hospital Sankt Augustin,
46 Sankt Augustin, Germany; ⁶Department of Pediatrics, Agaplesion Hospital Hagen, Hagen,
47 Germany; ⁷Division of Pediatric Intensive Care, Department of Pediatrics, Florence
48 Nightingale Hospital Kaiserswerth, Duesseldorf, Germany; ⁸Division of Pediatric Intensive
49 Care, Department of Pediatrics, Protestant Hospital Bethel, University of Bielefeld,
50 Bielefeld, Germany; ⁹Department of Pediatrics, Sankt Franziskus Hospital Muenster,

51 Muenster, Germany; ¹⁰Division of Neonatology, Department of Pediatrics, University
52 Hospital, RWTH University of Aachen, Aachen, Germany; ¹¹Division of Pediatric
53 Intensive Care, Department of Pediatrics, Sana Hospitals Duisburg, Duisburg, Germany;
54 ¹²Division of Neonatology, Department of Pediatrics and Adolescent Medicine, GFO
55 Hospital Bonn, Bonn, Germany; ¹³Department of General Pediatrics, DRK Hospital
56 Kirchen, Kirchen, Germany; ¹⁴Division of Pediatric Intensive Care, Department of
57 Pediatrics, Sankt Louise Hospital Paderborn, Paderborn, Germany; ¹⁵Department of
58 General Pediatrics, GFO Hospital Dinslaken, Dinslaken, Germany; ¹⁶Department of
59 Microbiology, University of Essen, Essen, Germany; ¹⁷Division of Pediatric Intensive Care,
60 Department of Pediatrics, University Hospital, University of Cologne, Cologne, Germany;
61 ¹⁸Department of General Pediatrics, Evangelical Hospital Oberhausen, Oberhausen,
62 Germany; ¹⁹Department of General Pediatrics, St. Franziskus-Hospital Ahlen, Ahlen,
63 Germany; ²⁰Department of General Pediatrics, Lukas-Hospital Neuss, Neuss, Germany;
64 ²¹Department of General Pediatrics, Märkisch Hospital Luedenscheid, Luedenscheid,
65 Germany; ²²Department of General Pediatrics, Evangelical Hospital Duesseldorf,
66 Duesseldorf, Germany; ²³Department of General Pediatrics, Marien-Hospital Witten,
67 Witten, Germany; ²⁴Department of General Pediatrics, Staedtische Kliniken
68 Moenchengladbach, Elisabeth-Hospital Rheydt, Moenchengladbach, Germany;
69 ²⁵Department of Pediatrics and Adolescent Medicine, Sankt Agnes Hospital, Bocholt,
70 Germany; ²⁶Department of General Pediatrics, Hospital Soest gGmbH, Soest, Germany;
71 ²⁷Division of Pediatric Intensive Care, Department of Pediatrics, Helios University Hospital
72 Wuppertal, Witten/Herdecke University, Wuppertal, Germany; ²⁸Department of General
73 Pediatrics, Mathias-Stiftung, Rheine, Germany; ²⁹Division of Pediatric Intensive Care,
74 Department of Pediatrics, Children's Hospital Amsterdamer Str., Cologne, Germany;
75 ³⁰Department of Pediatrics, Asklepios Clinic Sankt Augustin GmbH, Sankt Augustin,
76 Germany; ³¹Department of Pediatrics and Adolescent Medicine, Hochsauerland Hospital,
77 Arnsberg, Germany; ³²Department of General Pediatrics, Marien-Hospital gGmbH, Wesel,
78 Germany; ³³Department of Pediatrics, Gemeinschaftskrankenhaus Herdecke, University of
79 Witten/Herdecke, Herdecke, Germany; ³⁴Department of General Pediatrics, Hospital
80 Leverkusen GmbH, Leverkusen, Germany; ³⁵Division of Neonatology and Pediatric
81 Cardiology, Department of General Pediatrics, Heinrich Heine University, Duesseldorf,
82 Germany; ³⁶Department of Neonatology and Pediatric Intensive Care Medicine, University
83 of Bonn, Germany; ³⁷Department of General Pediatrics, Marien-Hospital Gelsenkirchen,
84 Gelsenkirchen, Germany; ³⁸Division of Oncology and Haematology, Departement of
85 General Pediatrics, Vestische Hospital of Children and Adolescents Medicine Datteln,
86 University of Witten/Herdecke, Datteln, Germany; ³⁹Department of Pediatrics, Elisabeth-
87 Hospital Essen, Essen, Germany; ⁴⁰Division of Pediatric Intensive Care, Department of
88 Pediatrics, Helios Hospital Krefeld, Krefeld, Germany; ⁴¹Department of General Pediatrics,
89 DRK Hospital Siegen gGmbH, Siegen, Germany; ⁴²Department of General Pediatrics, Porz,
90 Cologne, Germany; ⁴³Division of Neonatology and Pediatric Intensive Care, University
91 Children's Hospital, Ruhr University of Bochum, Bochum, Germany; ⁴⁴Department of
92 General Pediatrics, St. Antonius Hospital Kleve, Kleve, Germany; ⁴⁵Department of General
93 Pediatrics, Hospital Mechernich GmbH, Mechernich, Germany; ⁴⁶Department of Pediatrics,
94 Helios Clinic Duisburg, Duisburg, Germany; ⁴⁷Department of Pediatrics, Clemenshospital
95 Muenster, Muenster, Germany; ⁴⁸Department of General Pediatrics, Evangelical Hospital
96 Lippstadt, Lippstadt, Germany; ⁴⁹Department of General Pediatrics, municipal Hospital
97 Solingen, Solingen, Germany; ⁵⁰Department of Pediatrics, Helios Clinic Duisburg,
98 Duisburg, Germany; ⁵¹Division of Neonatology and Pediatric Intensive Care, Evangelical
99 Hospital Hamm, Hamm, Germany; ⁵²Department of General Pediatrics, Herford, Germany;
100 ⁵³Department of Pediatrics, St.-Clemens-Hospital Geldern, Geldern, Germany;
101 ⁵⁴Department of General Pediatrics, Sana-Hospital Remscheid, Remscheid, Germany;

⁵⁵Department of General Pediatrics, AKH Hospital Viersen, Viersen, Germany; ⁵⁶Division of Pediatric Intensive Care, Department of Pediatrics, University Hospital Muenster, Muenster, Germany; ⁵⁷Department of General Pediatrics, Hospital Oberhausen Sterkradeg GmbH, Oberhausen, Germany; ⁵⁸Department of General Pediatrics, Bethanien Hospital Moers, Moers, Germany; ⁵⁹Department of Pediatrics, Helios Medical Centre Niederberg, Velbert, Germany; ⁶⁰Division of Pediatric Intensive Care, Department of Pediatrics, Bergmannsheil Pediatric Hospital Gelsenkirchen Buer, Gelsenkirchen, Germany; ⁶¹Department of Pediatrics and Adolescent Medicine, Christophorus Hospital, Coesfeld, Germany; ⁶²German National Reference Laboratory for Meningococci and Haemophilus influenzae, Institute for Hygiene and Microbiology, University of Wuerzburg, Wuerzburg, Germany

Address correspondence to: Nora Bruns, Department of Pediatrics I (Neonatology, Pediatric Intensive Care, Pediatric Neurology, and Pediatric Infectious Diseases), University Hospital, Essen, University of Duisburg-Essen, Holsterhauserstr. 172, 40547 Essen, Germany, [nora.bruns@uk-essen.de], +49-201-723-83308.

Short title: Severe bacterial infections 2016 - 2023

Conflict of Interest Disclosures (includes financial disclosures): The other authors have no conflicts of interest to disclose.

Funding/Support: This research received no external funding. The surveillance of invasive streptococcal infections in Germany at the German National Reference Laboratory for Streptococci was funded by the Robert Koch Institute, Berlin, Germany (funding number: 1369-235)

Role of Funder/Sponsor (if any): The funder had no role in the design and conduct of the study.

Clinical Trial Registration (if any): n/a

Abbreviations: CI = confidence interval, CNS = central nervous system, CRC = capture-recapture, eCRF = web-based case report forms, ENT = ears nose and throat, FSO = Federal State Office, *H. influenzae* = *Haemophilus influenzae*, ICD-10-GM = international classification of diseases 10 German modification, IQR = interquartile range, IRR = incidence rate ratios, MC = multicentre study, *N. meningitidis* = *Neisseria meningitidis*, NRL = National Reference Laboratories, NRLMHi = National Reference Laboratory for *N. meningitidis* and *H. influenzae*, NRW = North Rhine-Westphalia, PCPC = pediatric cerebral performance category, PICU = pediatric intensive care unit, rRNA = ribosomal Ribonucleic acid, RSV = respiratory syncytial virus, *S. pneumoniae* = *Streptococcus pneumoniae*, *S. pyrogenes* = *Streptococcus pyogenes*, SIRS = systemic inflammatory response syndrome

153

154

155

156 **Article Summary**

157 In late 2022 and early 2023, hospitalizations for bacterial infections dramatically increased,
158 causing deaths and contributing to a near-collapse of the pediatric health care system.

159

160

161

162 **What's Known on This Subject**

163 During the COVID-19 pandemic, incidences of bacterial infections strongly declined. In
164 late 2022, several European countries observed strongly rebounding incidences of invasive
165 infections from group A streptococci.

166

167

168 **What This Study Adds**

169 This study found up to 18-fold incidence rates of *S. pyogenes* in late 2022 and early 2023,
170 accompanied by surges of *S. pneumoniae* and partially *H. influenzae*. Deaths were seven
171 times higher than expected.

172

173

174 **Contributors Statement Page**

175

176 Drs. Sarah C. Goretzki and Nora Bruns conceptualized and designed the study, carried out
177 analyses, drafted the initial manuscript, and critically reviewed and revised the manuscript.

178

179 Drs Tom Hühne, Roland O. Adelman, Firas Ala Eldin, Mohamed Albarouni, Jan-Claudius
180 Becker, Michael A. Berghäuser, Thomas Boesing, Michael Boeswald, Milian Brasche,
181 Francisco Brevis, Rokya Camara, Clara Deibert, Frank Dohle, Jörg Dolgner, Jan Dziobaka,
182 Frank Eifinger, Natalie Elting, Matthias Endmann, Holger Frenzke, Monika Gappa,
183 Bahman Gharavi, Christine Goletz, Eva Hahn, Yvonne Heidenreich, Konrad Heimann,
184 Hans-Georg Hoffmann, Marc Hoppenz, Gerd Horneff, Helene Klassen, Cordula Körner-
185 Rettberg, Pascal Lenz, Klaus Lohmeier, Andreas Müller, Frank Niemann, Michael
186 Paulussen, Falk Pentek, Ruy Perez, Markus Pingel, Philip Repges, Tobias Rothoef, Jochen
187 Rübo, Herbert Schade, Robert Schmitz, Peter Schonhoff, Jan N. Schwade, Tobias
188 Schwarz, Peter Seiffert, Georg Selzer, Uwe Spille, Carsten Thiel, Ansgar Thimm,
189 Bartholomäus Urgatz, Alijda van den Heuvel, Tan van Hop, Verena Giesen, Stefan Wirth,
190 Thomas Wollbrink, Daniel Wüller and Profs. Guido Engelmann, Kai O. Hensel, Alfred
191 Längler, collected data and critically reviewed and revised the manuscript.

192

193 Drs. Mark van der Linden, Andreas Itzek, Heike Claus and Thiên-Trí Lâm collected data,
194 carried analyses, and critically reviewed and revised the manuscript.

195

196 Profs. Ursula Felderhoff-Müser and Christian Dohna-Schwake conceptualized and
197 designed the study, coordinated and supervised data collection, and critically reviewed and
198 revised the manuscript for important intellectual content.

199

200 All authors approved the final manuscript as submitted and agree to be accountable for all
201 aspects of the work.

202

203

204

205 **Abstract [250 words max]**

206

207 **Background:**

208 In late 2022, a surge of severe bacterial infections caused by *S. pyogenes* was reported in
209 several European countries, including Germany. This study assessed disease burden and
210 severity of hospitalizations for community-acquired bacterial infections with *S. pyogenes*,
211 *S. pneumoniae*, *N. meningitidis*, and *H. influenzae* among children in North Rhine-
212 Westphalia (NRW), Germany, during the last quarter of 2022 compared to long-term
213 incidences.

214

215 **Methods:**

216 Hospital cases due to bacterial infections between October and December 2022 were
217 collected from 59/62 (95 %) children's hospitals in NRW and combined with surveillance
218 data (2016 - 2023) from the national reference laboratories for streptococci, *N.*
219 *meningitidis*, and *H. influenzae*. Total cases in NRW and incidence rates from January 2016
220 to March 2023 were estimated by capture-recapture analyses. Expected annual deaths from
221 the studied pathogens were calculated from national death cause statistics.

222

223 **Results:**

224 Between October and December 2022, 153 cases with high overall disease severity were
225 reported with pneumonia being most common (59 %, n = 91). Incidence rates of bacterial
226 infections declined at the beginning of the COVID-19 pandemic. In late 2022 and early
227 2023 a massive surge to levels unprecedented since 2016 was observed, mainly driven by *S.*
228 *pyogenes* and *S. pneumoniae*. Observed deaths during the study period exceeded the
229 expected number for the entire year in NRW by far (7 vs. 0.9).

230

231 **Discussion:**

232 The unprecedented peak of bacterial infections in late 2022 and early 2023 was caused by
233 various mechanisms intertwined that require close surveillance and improved precautionary
234 measures for future outbreaks.

235 **Introduction**

236 Since the outbreak of the COVID-19 pandemic in 2020, children's and adolescents'
237 health has been challenged in numerous ways. Among others, a decline of bacterial
238 infections and distorted periodicity of seasonal infection waves were observed across the
239 world and affected all age groups.¹⁻⁵ An unforeseen result of reduced incidence of
240 infections is the lack of natural immunity especially in the youngest.

241 Beginning in late fall 2022, rising numbers of severe bacterial infections caused by
242 group A streptococci were reported from Spain, France, Great Britain, and other
243 countries.⁶⁻⁹ At the same time in Germany, a massive wave of acute viral and bacterial
244 infections caused a near-collapse of the pediatric health care system including out- and
245 inpatient sectors and - most dramatically - overwhelmed pediatric intensive care
246 capacities.¹⁰⁻¹² Pediatric health care providers in Germany claimed that this was an
247 unprecedented public health emergency.

248 This study was designed to assess the burden of hospitalizations due to community-
249 acquired bacterial infections by *Streptococcus pyogenes* (*S. pyogenes*),
250 *Streptococcus pneumoniae* (*S. pneumoniae*), *Neisseria meningitidis* (*N. meningitidis*),
251 and *Haemophilus influenzae* (*H. influenzae*) in the last quarter of 2022 compared to
252 seasonally expected infection waves since 2016; to identify driving pathogens, and
253 describe disease severity and outcomes. Accordingly, we combined five data sources for
254 comprehensive capture-recapture analyses: 1) A multicentre study (MC) conducted in
255 95 % of children's hospitals in the most populated state of Germany (North Rhine-
256 Westphalia [NRW]) in the last quarter of 2022; 2) long-term surveillance data from
257 national reference laboratories for a) streptococci, b) *N. meningitidis*, and c)
258 *Haemophilus influenzae*; as well as 3) publicly accessible population and death cause
259 statistics provided by the German Federal Statistical Office (FSO, Statistisches

260 Bundesamt, www.destatis.de).

261

262

263 **Methods**

264 Study design:

265 This is a retrospective multicentre cohort study to assess the burden of community-
266 acquired severe bacterial infections in children and adolescents in NRW/Germany
267 (NRW) between October 1st and December 31st of 2022. The results were combined
268 with four data sources to deduce long-term trends.

269 First, clinical data were collected from 60 of 63 (95 %) children's hospitals in NRW.

270 Second, surveillance data from the national reference laboratories (NRL) for
271 streptococci, *N. meningitidis*, and *H. influenzae* were matched with clinical cases from
272 the same period to conduct capture-recapture (CRC) analyses for each pathogen. Third,
273 monthly NRL-reported incidence numbers between January 2016 and March 2023 were
274 combined with population statistics published by the FSO to calculate incidence rates
275 and ratios. Fourth, death statistics by the FSO were accessed to calculate the expected
276 number of deaths by bacterial infections per year and compare them with the numbers
277 observed in the MC study.

278

279 Multicentre study

280 Study population:

281 Children aged > 27 days and < 18 years admitted to a children's hospital in NRW during
282 the study period due to a community-acquired infection with *S. pyogenes*,
283 *S. pneumoniae*, *N. meningitidis*, or *H. influenzae* were eligible. Children with catheter-
284 associated infections from permanently indwelling catheters and cases of nosocomial
285 infections were excluded.

286

287 Clinical data collection:

288 Executives of all children's hospitals in NRW were invited to participate. Eligible
289 patients were identified via positive test results for the bacterial pathogen of interest by
290 the local microbiology departments or derived from diagnose related group codes
291 (International Classification of Diseases, 10th revision, German modification). Eligibility
292 was confirmed via retrospective chart review by the local investigators. Anonymized
293 clinical data were collected via web-based case report forms (eCRF) hosted at
294 www.limesurvey.org.

295

296 Handling of duplicates:

297 Duplicate reports in the dataset originating from inter-centre referrals were identified by
298 discharge date information and destination of referral in the eCRF. The total duration of
299 hospital stay in both hospitals was updated along with clinical information, and the
300 duplicate case removed.

301

302 Children's hospital capacities of North Rhine-Westphalia:

303 Each participating hospital reported the number of non-surgical beds on pediatric wards
304 (including neonatal and pediatric intensive care units) during the study period in the
305 eCRFs. The capacities of the three non-participating centres were obtained by personal
306 inquiry to the attending office of the respective children's hospital.

307

308 National surveillance of invasive bacterial infections

309 - Streptococci:

310 Reporting of invasive *S. pneumoniae* infections is mandatory in Germany. However,
311 surveillance of invasive streptococcal disease by the German national reference

312 laboratory for streptococci (NRLS) is based on voluntary reporting by primary
313 diagnostic laboratories, which are requested to send all streptococcal isolates from
314 invasive infections (isolate sampled from a normally sterile anatomical site) to the
315 NRLS for detailed analyses. This includes mainly microbiological- (hemolysis- and
316 colony-size assessment, optochin sensitivity as well as bile solubility), biochemical-
317 (leucine-aminopeptidase- and pyrrolidonylarylamidase-test), serological- (Neufeld-
318 Quellung reaction) and molecularbiological methods (*16S rRNA* sequencing, *emm*-
319 typing).

320

321 - *N. meningitidis* and *H. influenzae*:

322 Mandatory reporting is required for cases of meningococcal meningitis and
323 meningococcal septicaemia. Additionally, the detection of *N. meningitidis* in blood,
324 cerebrospinal fluid, petechiae, or other sterile sites, as well as the detection of
325 *H. influenzae* in blood or cerebrospinal fluid, must be reported. While it is voluntary to
326 submit bacterial isolates or clinical specimens to the National Reference Laboratory for
327 *N. meningitidis* and *H. influenzae* (NRLMHi), up to 90% of the reported cases are
328 covered by the submissions to NRLMHi. Following species confirmation,
329 meningococcal serogroups and *H. influenzae* serotypes are determined through slide
330 agglutination using specific commercial antibodies.

331

332 Population statistics of NRW:

333 The end of year-populations of NRW and Germany from 2015 through 2022 were
334 accessed at the FSO homepage (www.destatis.de). This information was used to
335 calculate midyear populations as well as inhabitant percentage of children < 18 years of
336 age.

337

338 National death cause statistics:

339 Nationwide death cause statistics were accessed at the FSO homepage and the yearly
340 numbers of deaths from streptococci, *N. meningitidis*, and *H. influenzae* infections were
341 extracted for 2016 to 2021 based on the diagnose code of the international classification
342 of diseases 10 German modification (ICD-10-GM) (Table 1). Because age grouping
343 available at the FSO does not comply with the cut-off age for treatment in pediatric
344 departments, expected deaths were calculated only for children < 15 years of age. The
345 number of nationwide expected deaths per year was extrapolated based on the
346 proportion of the pediatric population of NRW (22 %) compared to the total pediatric
347 population of Germany.

348

349 Linkage of clinical and surveillance data:

350 Clinical MC and NRL surveillance data of *S. pyogenes*, *S. pneumoniae*, *N. meningitidis*
351 and *H. influenzae* were matched by patient's age, sex, sample collection site and date,
352 identified pathogen and serotype if applicable. Direct record linkage by name or date of
353 birth was inapplicable due to anonymization and prohibited by general data protection
354 regulations.

355

356 Statistical analyses:

357 Continuous variables are presented as means with 95 % confidence intervals (CI) if
358 evenly distributed and as median with interquartile range (IQR) if skewed. Discrete
359 variables are presented as counts and relative frequencies. Descriptive statistics were
360 stratified by pathogen. The dataset of the MC study contained no missing data.

361 Capture-recapture analyses (CRC) were conducted using a generalized log-linear model
362 with Poisson distribution to estimate the number of non-captured cases with 95 % CIs
363 and calculated the estimated number of total cases. Stratification to account for age-,

364 sex- or centre-specific probabilities could not be performed due to the overall low case
365 numbers.

366 Monthly incidence rates per 100.000 child years (CY) were derived from total case
367 numbers estimated by CRC analyses assuming a consistent reporting rate over time.

368 Monthly incidence rate ratios (IRR) were calculated for the period from January 2020 to
369 March 2023, with the corresponding months of 2016-2019 as references. Besides
370 pathogen-specific incidence rates and IRRs, cumulative monthly incidence rates and
371 IRRs for all four pathogens were calculated to assess the overall burden. 95 % CIs for
372 rates and rate ratios were calculated based on the Poisson distribution.

373 SAS Enterprise Guide 8.3 (SAS Institute Inc., Cary, NC, USA) was used to perform
374 statistical analyses and produce figures.

375

376 Ethics approval

377 The study was approved by the Ethics Committee of the Medical Faculty of the
378 University of Duisburg-Essen (22-11045-BO).

379

380

381 **Results**

382 Fifty-nine of 62 (95 %) children's hospitals in NRW participated in the MC study,
383 comprising 4066 of 4323 (94 %) self-reported pediatric hospital beds during the study
384 period. At the end of 2022, 22 % of Germany's pediatric population lived in NRW.
385 After subtracting the 6 % capacities from non-participating children's hospitals, the
386 participating centers supplied medical care for approximately 20.7 % of the German
387 pediatric population.

388 A total of 153 cases were reported with a median patient age of 4 years (IQR 1 – 7) and
389 56 % (n = 86) males (Table 2). Fifty-eight (38 %) of the reported cases were associated

390 with *S. pyogenes*, 62 (41 %) with *S. pneumoniae*, 2 (1 %) with *N. meningitidis*, 19 (12
391 %) with *H. influenzae*, and 12 (8 %) with other streptococcal species. The most frequent
392 presentation was pneumonia (n = 91, 59 %), followed by sepsis/systemic inflammatory
393 response syndrome/toxic shock syndrome (n = 28, 18 %), skin or soft tissue infections (n
394 = 22, 14 %), and ear-nose-throat infections without cerebral invasion (n = 22, 14 %)
395 (Table 2). Viral co-infections were observed in 71 (46%) cases, with variations
396 depending on the bacterial pathogen (Table 2). Intensive care unit admissions were
397 frequent (n = 90, 59%), as was mechanical ventilation (n = 67, 44 %), surgical source
398 control (n = 41, 27 %), and use of vasopressors or inotropes (n = 26, 17 %) (Table 2).
399 Substantial variation between pathogens was observed regarding clinical presentation
400 and performed supportive therapies (Figure 1). Eight children died (5 %), and five
401 patients (3 %) were discharged to a rehabilitation or care facility. Nonetheless, overall
402 functional neurological outcome at hospital discharge in survivors was good (median
403 pediatric cerebral performance category (PCPC) = 1, IQR 1 – 2).

404 Capture-recapture analyses showed different degrees of overlap between the conducted
405 MC study and the NRL surveillance data. For *N. meningitidis*, complete capture by the
406 NRL was achieved, but the total case number (n = 6) was comparatively low, especially
407 when compared to case estimates of *S. pneumoniae* (n_{estimated} = 232), *S. pyogenes*
408 (n_{estimated} = 214), and *H. influenzae* (n_{estimated} = 95) (Table 3).

409 With onset of the COVID-19 pandemic, monthly *S. pyogenes* case numbers reported to
410 the NRLS, monthly incidence rates and IRRs dropped, remained low until September
411 2022 and peaked in December 2022 (IRR 18.3 (95 % CI 6.3 – 88.8)) as well as March
412 2023 (IRR 14.7 (5.7 – 54.0)) (Figure 2a and S1a). *S. pneumoniae* also showed a decline
413 during pandemic years but seasonal variations remained present throughout the three-
414 year period, with a remarkable peak in December 2022 (IRR 2.7 (1.7 – 4.7)) and
415 February 2023 (IRR 3.2 (2.0 – 5.5)) (Figure 2b and S1b). For *N. meningitidis*, overall

416 case numbers were fairly low and no clear trend was observed throughout the
417 observation period except for an increase in March 2023 (IRR 1.7 (1.0 – 3.1)) (Figure 2c
418 and S1c). *H. influenzae*, on the other hand, remained mainly within the seasonally
419 expected ranges except for November 2022 (IRR 7.8 (2.2 – 64.8)) and February 2023
420 (IRR 2.9 (1.1 – 10.8)) (Figure 2d and S1c). Overall, incidence rates and IRRs exhibited a
421 decline at the onset of the pandemic, followed by a pathogen-specific degree of
422 recovery, reaching or surpassing pre-pandemic levels (Figure S1 and supplementary
423 table). Cumulative monthly incidence rates and IRRs declined at the beginning of the
424 pandemic, showed small peaks during the course of the pandemic, and peaked in
425 December 2022 and February 2023 (Figure 3 and supplementary table).

426 During the three-month MC study, the reported number of deaths in children < 15 years
427 of age exceeded the expected number of deaths from bacterial infections for the entire
428 year in NRW (7 observed; 1 expected). The causative pathogens were identified as
429 *S. pyogenes* and *S. pneumoniae*, while no deaths were caused by *N. meningitidis* (2
430 expected) (Table 4).

431

432 **Discussion**

433 This multi-source study in Germany's most populous federal state detected a high
434 burden of pediatric general ward and pediatric intensive care unit admissions for
435 bacterial infections associated with *S. pyogenes*, *S. pneumoniae*, *N. meningitidis*, and *H.*
436 *influenzae* in the last quarter of 2022. Disease severity was high with more than half of
437 the cases admitted to an intensive care unit and frequent requirement of invasive
438 mechanical ventilation and vasoactive agents. Longitudinal assessment since 2016
439 revealed an unprecedented peak of bacterial infection-related hospitalizations in late
440 2022 and early 2023, primarily driven by *S. pyogenes* and *S. pneumoniae*. Deaths during
441 the three-month period of the MC study were seven times higher than expected for the

442 entire year according to pre-pandemic death cause statistics.

443 A major finding that has already been reported in adults and children^{13,14} was the marked
444 overall decline of severe and invasive bacterial infections at the beginning of the
445 COVID-19 pandemic. According to our study, this overall decline was shortly
446 interrupted in fall 2021 but otherwise lasted until early summer 2022 when compulsory
447 wearing of protective face masks was abrogated. However, decline patterns differed
448 between the four bacterial pathogens examined in this study and were likely influenced
449 by other factors than protective face masks.^{13, 15-20}

450 The decline of *S. pyogenes* infections from the onset of the pandemic until spring 2022
451 was also reported in France, followed by a sudden increase of non-invasive *S. pyogenes*
452 infections.²¹ Similar to Germany, France and England also witnessed strong increases of
453 severe and invasive *S. pyogenes* infections during fall and winter of 2022.^{7, 22} These
454 surges were most likely induced by an overall rise in infection numbers with the
455 proportion of severe cases remaining constant, rather than changes in types, virulence or
456 toxicity.^{7, 23-25} A possible explanation is the discontinuation of face mask wearing among
457 children, which re-enabled droplet transmission of *S. pyogenes*, an essential mechanism
458 of infection.²⁶ Acute viral infections paving the way for bacterial superinfections are an
459 additional factor potentially contributing to the severity of the *S. pyogenes* infection
460 wave. This constellation is described for influenza virus in combination with *S.*
461 *pyogenes* and *S. pneumoniae*²⁷ and was also observed in our study. The theory of
462 superinfections as partial drivers of the surge is supported by the rise in consultations
463 and hospitalizations for severe acute respiratory disease in children and adolescents
464 during the peak of *S. pyogenes* infections in Germany in late 2022 reported by the
465 Robert Koch-Institute.²⁸

466 Viral infections likely also promoted the increase of *S. pneumoniae* infections.

467 Asymptomatic *S. pneumoniae* carriage and respiratory virus infection as starting point
468 for invasive pneumococcal disease is well-described.²⁹ Our study found viral co-
469 infections in 60 % of the *S. pneumoniae* cases, with influenza and respiratory syncytial
470 virus as the most common. During the pandemic years, the decline in pneumococcal
471 infections in Germany was less consistent compared to the drop in *S. pyogenes*
472 infections, possibly explained by viral infection waves among children in spite of the
473 pandemic measures.²⁸ In contrast to *S. pyogenes* infections, invasive pneumococcal
474 disease can be effectively prevented by vaccination.³⁰ Consequently, it is crucial to
475 establish and maintain high levels of vaccination rates to attenuate future outbreaks
476 triggered by viral waves. In Germany, pneumococcal vaccination coverage for children
477 entering primary school increased from 15 % in 2010 to 83 % in 2017-2019 but is as low
478 as 2 % in the age group from 16 to 59 years, even in patients who suffer from high-risk
479 clinical conditions.^{31, 32} Of infants born in 2016, only 73 % received a full series of the
480 recommended pneumococcal vaccination scheme, vaccinations were frequently delayed,
481 and nearly a quarter of infants did not receive a booster dose.³³ This low vaccination
482 coverage calls for urgent improvement to enhance protection against opportunistic
483 pneumococcal infections during large-scale viral waves that are expected to persist in
484 the post-SARS-CoV-2 era.

485 Vaccines are also responsible for decreasing incidence rates of meningococcal infections
486 with marked replacement by non-vaccinated serogroups W and Y in several countries.³⁴
487 In Germany, vaccination is recommended for serogroup C with an according decline of
488 serogroup C infections since its introduction.³⁵ The trend of overall decreasing
489 meningococcal disease was further enhanced during the COVID-19 pandemic¹³ and also
490 noticeable in our study with incidence rates below pre-pandemic average. Yet, in March
491 2023, an increase in meningococcal infection incidence above average was observed but

492 characterized by very low absolute numbers. In contrast to *S. pneumoniae*, vaccine
493 coverage against meningococcal serogroup C in school starters in Germany is above 90
494 %.³² Unfortunately, no data are available on *N. meningitidis* serogroup B, but vaccine
495 coverage is likely to be very low because vaccination is not officially recommended and
496 thus not routinely covered by health insurances.

497 In the Netherlands, a decline of invasive infections during the COVID-19 pandemic was
498 observed for *H. influenzae*, unfortunately associated with an increase of vaccine-
499 preventable serotype b.³⁶ In our study, *H. influenzae* hospitalizations during the
500 pandemic remained within seasonally expected ranges, showing only two peaks in
501 December of 2021 and 2022, respectively. However, despite vaccine coverage of 90 %
502 in German children against *H. influenzae b*³², IRRs have remained almost constantly
503 above one since June 2021, indicating a slight increase of non-vaccinated *H. influenzae*
504 infections that contribute to the overall burden of pediatric hospitalizations, especially
505 during seasonal waves of acute respiratory diseases.

506 Limitations of the study mainly derive from missing cases: Due to the incomplete
507 coverage of children's hospitals in NRW, the MC study missed 6 % of pediatric hospital
508 capacities. Cases treated outside of pediatric units, such as otorhinolaryngology or adult
509 units, and pre-hospital deaths could not be captured, potentially leading to
510 underestimation of incidences and disease severity. Variable pathogen-specific
511 underreporting to the NRLs was also observed, which is acknowledged for infectious
512 disease surveillance.³⁷⁻³⁹

513 In summary, the acute overload of the German pediatric health care system was caused
514 by a post-pandemic rebound of acute viral and bacterial respiratory and invasive
515 diseases that peaked at the same time, creating a fatal combination that caused an
516 unprecedented incidence of hospitalizations in children. Shortages of essential drugs in

517 the outpatient sector^{40, 41} and a decrease in numbers of operable beds in children's
518 hospitals due to long-anticipated personnel shortages^{42, 43} aggravated this pediatric health
519 care crisis.

520 The results of this study present another piece of evidence that the side effects from
521 preventive measures against the COVID-19 pandemic are at least on par with the harm
522 children experienced from the novel coronavirus itself. While this is already well-
523 acknowledged for mental health and obesity, which directly increase morbidity but not
524 mortality⁴⁴⁻⁴⁷, the wide-spread and drastic increase of severe and fatal bacterial
525 infections in developed countries is new. Worldwide shortages of antibiotics for children
526^{40, 41} complicated early treatment in the outpatient setting, which may have caused
527 exacerbation of some cases. Despite good overall functional neurological outcomes
528 observed in this study, non-neurological long-term sequelae, especially
529 poststreptococcal autoimmune disorders, may continue to burden the health care system
530 for years.

531 Further research should untangle this amalgam to quantify excess morbidity and
532 mortality that result from acute bacterial infections themselves and from the failure to
533 provide adequate pediatric care capacities in Germany. However, even more urgent than
534 scientific workup, is the introduction of effective measures against future outbreaks
535 among children to prevent morbidity and deaths. These include high vaccination
536 coverage, opportunity to acquire natural immunity against viral and bacterial disease,
537 sufficient pediatric drug supply, and pediatric health care capacities adapted to seasonal
538 demands.

539

540 Conclusion

541 The German pediatric health care crisis in late 2022 and early 2023 was caused by

542 various mechanisms: an increased number of circulating bacterial pathogens, reduced
543 adaptive immunity in the pediatric population following COVID-19 pandemic isolation
544 measures, high burden of simultaneous viral infections, shortage of pediatric hospital
545 capacities, and deficient pediatric antibiotic supply. Considering the upcoming infection
546 season, an effective action plan including preventive measures needs to be combined
547 with ongoing infection surveillance to prevent a possible new crisis in pediatric health
548 care.
549

Acknowledgments

We thank Christina Pentek for her logistic support.

References

1. Eden JS, Sikazwe C, Xie R, Deng YM, Sullivan SG, Michie A, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. *Nat Commun.* 2022;13(1):2884.
2. Rao S, Armistead I, Messacar K, Alden NB, Schmoll E, Austin E, et al. Shifting Epidemiology and Severity of Respiratory Syncytial Virus in Children During the COVID-19 Pandemic. *JAMA Pediatr.* 2023.
3. Farfour E, Clichet V, Péan de Ponfilly G, Carbonnelle E, Vasse M. Impact of COVID-19 pandemic on blood culture practices and bacteremia epidemiology. *Diagn Microbiol Infect Dis.* 2023;107(1):116002.
4. Ricketson LJ, Kellner JD. Changes in the Incidence of Invasive Pneumococcal Disease in Calgary, Canada, during the SARS-CoV-2 Pandemic 2020-2022. *Microorganisms.* 2023;11(5).
5. Amarsy R, Robert J, Jarlier V. [Impact of the first year of the COVID-19 pandemic on the epidemiology of invasive infections (bacteremia) in the hospitals of the Assistance Publique-Hôpitaux de Paris]. *Bull Acad Natl Med.* 2023;207(2):131-135.
6. Cobo-Vázquez E, Aguilera-Alonso D, Carrasco-Colom J, Calvo C, Saavedra-Lozano J. Increasing incidence and severity of invasive Group A streptococcal disease in Spanish children in 2019-2022. *Lancet Reg Health Eur.* 2023;27:100597.
7. Guy R, Henderson KL, Coelho J, Hughes H, Mason EL, Gerver SM, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. *Euro Surveill.* 2023;28(1).
8. Lassoued Y, Assad Z, Ouldali N, Caseris M, Mariani P, Birgy A, et al. Unexpected Increase in Invasive Group A Streptococcal Infections in Children After Respiratory Viruses Outbreak in France: A 15-Year Time-Series Analysis. *Open Forum Infectious Diseases.* 2023;10(5):ofad188.
9. Organization WH. Increased incidence of scarlet fever and invasive Group A Streptococcus infection - multi-country. <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429>. Published 2022. Accessed July 15th, 2022.
10. Recent hospital survey reveals: On average, no available intensive care bed for critically ill children - Emergency physicians demand new structures. www.divi.de2022.
11. <https://www.dw.com/en/germany-rsv-infection-wave-overloads-childrens-hospitals/a-63963430>. www.dw.com2023.
12. "Children are dying because we cannot provide them with care." www.welt.de: Welt; 2022.
13. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet Digit Health.* 2021;3(6):e360-e370.
14. McNeil JC, Flores AR, Kaplan SL, Hulten KG. The Indirect Impact of the SARS-CoV-2 Pandemic on Invasive Group a Streptococcus, Streptococcus Pneumoniae

- and Staphylococcus Aureus Infections in Houston Area Children. *Pediatr Infect Dis J.* 2021;40(8):e313-e316.
15. Messacar K, Baker RE, Park SW, Nguyen-Tran H, Cataldi JR, Grenfell B. Preparing for uncertainty: endemic pediatric viral illnesses after COVID-19 pandemic disruption. *Lancet.* 2022;400(10364):1663-1665.
 16. Turner CE. Can group A streptococcus infections be influenced by viruses in the respiratory tract? *Lancet Infect Dis.* 2023;23(2):142-144.
 17. Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. *Front Microbiol.* 2017;8:1041.
 18. Thorburn K, Harigopal S, Reddy V, Taylor N, Saene HKFv. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. *Thorax.* 2006;61(7):611.
 19. Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. *Expert Rev Vaccines.* 2017;16(4):313-328.
 20. Hellenbrand W, Koch J, Harder T, Bogdan C, Heininger U, Tenenbaum T, et al. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2015;58(11-12):1314-1343.
 21. Cohen JF, Rybak A, Werner A, Kochert F, Cahn-Sellem F, Gelbert N, et al. Surveillance of noninvasive group A Streptococcus infections in French ambulatory pediatrics before and during the COVID-19 pandemic: a prospective multicenter study from 2018-2022. *Int J Infect Dis.* 2023;134:135-141.
 22. van Kempen EB, Bruijning-Verhagen PCJ, Borensztajn D, Vermont CL, Quaak MSW, Janson J-A, et al. Increase in Invasive Group a Streptococcal Infections in Children in the Netherlands, A Survey Among 7 Hospitals in 2022. *The Pediatric Infectious Disease Journal.* 2023;42(4).
 23. de Gier B, Marchal N, de Beer-Schuurman I, te Wierik M, Hooiveld M, Group I-AS, et al. Increase in invasive group A streptococcal (*Streptococcus pyogenes*) infections (iGAS) in young children in the Netherlands, 2022. *Eurosurveillance.* 2023;28(1):2200941.
 24. Johannesen TB, Munkstrup C, Edslev SM, Baig S, Nielsen S, Funk T, et al. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent *Streptococcus pyogenes* M1 clone, Denmark, 2023. *Eurosurveillance.* 2023;28(26):2300291.
 25. Robert-Koch-Institut. Update: Anstieg bakterieller Infektionen durch Gruppe-A-Streptokokken, Pneumokokken und *Haemophilus influenzae* in Deutschland seit Ende 2022. Berlin: Robert-Koch-Institut; 2023 February 23rd, 2023. Report No.: 8.
 26. Avire NJ, Whiley H, Ross K. A Review of *Streptococcus pyogenes*: Public Health Risk Factors, Prevention and Control. *Pathogens.* 2021;10(2).
 27. Oliver J, Thielemans E, McMinn A, Baker C, Britton PN, Clark JE, et al. Invasive group A *Streptococcus* disease in Australian children: 2016 to 2018 – a descriptive cohort study. *BMC Public Health.* 2019;19(1):1750.
 28. Buda S, Du□rrwald R, Biere B, Reiche J, Buchholz U, Tolksdorf K, et al. ARE-Wochenbericht KW 25/2023. *Arbeitsgemeinschaft Influenza – Robert Koch-Institut.* 2023.
 29. Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of

- Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. *Clin Infect Dis*. 2022;75(1):e1154-e1164.
30. Chesdachai S, Graden AR, DeSimone DC, Weaver AL, Baddour LM, Joshi AY. Changing Trends of Invasive Pneumococcal Disease in the Era of Conjugate Pneumococcal Vaccination in Olmsted County: A Population-Based Study. *Mayo Clin Proc*. 2022;97(12):2304-2313.
 31. Deb A, Podmore B, Barnett R, Beier D, Galetzka W, Qizilbash N, et al. Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany. *BMC Infectious Diseases*. 2022;22(1):753.
 32. Vaccination coverage of children presenting their vaccination card at school entry health examinations. https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_menu_olap?p_uid=gast&p_aid=34430128&p_sprache=E&p_help=0&p_indnr=831&p_indsp=27110398&p_ityp=H&p_fid=. Published 2023. Accessed July 2nd, 2023.
 33. Laurenz M, von Eiff C, Borchert K, Jacob C, Seidel K, Schley K. Vaccination rates and adherence in pneumococcal conjugate vaccination in mature born infants before and after vaccination schedule change – A claims database analysis. *Vaccine*. 2021;39(24):3287-3295.
 34. Nuttens C, Findlow J, Balmer P, Swerdlow DL, Tin Tin Htar M. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. *Euro Surveill*. 2022;27(3).
 35. Robert-Koch-Institut. Invasive Meningokokken-Erkrankungen 2012 – 2015. Berlin: Robert-Koch-Institut; 2016 October 31st, 2016.
 36. Steens A, Knol MJ, Freudenburg-de Graaf W, de Melker HE, van der Ende A, van Sorge NM. Pathogen- and Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands. *Microorganisms*. 2022;10(5).
 37. Doyle TJ, Glynn MK, Groseclose SL. Completeness of Notifiable Infectious Disease Reporting in the United States: An Analytical Literature Review. *American Journal of Epidemiology*. 2002;155(9):866-874.
 38. Meadows AJ, Oppenheim B, Guerrero J, Ash B, Badker R, Lam CK, et al. Infectious Disease Underreporting Is Predicted by Country-Level Preparedness, Politics, and Pathogen Severity. *Health Secur*. 2022;20(4):331-338.
 39. Gibbons CL, Mangen M-JJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. *BMC Public Health*. 2014;14(1):147.
 40. Shachar C, Gruppuso PA, Adashi EY. Pediatric Drug and Other Shortages in the Age of Supply Chain Disruption. *Jama*. 2023;329(24):2127-2128.
 41. Reali L, Mendie C, Fischbach T, Werner A, Leitner AY, Karall D, et al. Open letter: The health of our children and adolescents is endangered throughout Europe due to the medication shortage. www.bvkJ.de2023.
 42. Parvu V. Alarming study results: Physicians warn of supply crisis in German children's hospitals. www.divi.de2019.
 43. DIVI criticizes staff shortage in pediatric intensive care units in Germany. www.divi.de2018.
 44. Chang TH, Chen YC, Chen WY, Chen CY, Hsu WY, Chou Y, et al. Weight Gain Associated with COVID-19 Lockdown in Children and Adolescents: A Systematic Review and Meta-Analysis. *Nutrients*. 2021;13(10).
 45. Viner R, Russell S, Saulle R, Croker H, Stansfield C, Packer J, et al. School Closures During Social Lockdown and Mental Health, Health Behaviors, and Well-

- being Among Children and Adolescents During the First COVID-19 Wave: A Systematic Review. *JAMA Pediatr.* 2022;176(4):400-409.
46. Bruns N, Willemsen L, Stang A, Kowall B, Holtkamp K, Kamp O, et al. Pediatric Intensive Care Unit Admissions After Adolescent Suicide Attempts During the Pandemic. *Pediatrics.* 2022.
47. Meherali S, Punjani N, Louie-Poon S, Abdul Rahim K, Das JK, Salam RA, et al. Mental Health of Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic Review. *Int J Environ Res Public Health.* 2021;18(7).

Tables

Table 1: International classification of diseases codes used to calculate the number of expected deaths from bacterial infections in children in Germany

Pathogen	ICD-10-GM code
Streptococci (all species)	A40.0-A40.3, A40.8, A40.9, A46, A49.1, G00.1, G00.2, J03.0, J13, J15.3, J15.4, J20.2, M00.2, J02.0
<i>N. meningitidis</i>	A39.0-A39.4, A39.8, A39.9
<i>H. influenzae</i>	A41.3, A49.2, J14

ICD-10-GM = international classification of diseases 10 (German modification)

Table 2: Clinical characteristics of hospital admissions due to bacterial infections reported in a multicentre study in children's hospitals in North Rhine-Westphalia (Germany) between October 1st and December 31st, 2022

	Total	<i>S. pyogenes</i>	<i>S. pneumoniae</i>	<i>H. influenzae</i>	<i>N. meningitidis</i>	<i>S. spp.*</i>
	N = 153 (100%)	n = 58 (38 %)	n = 62 (41 %)	n = 19 (12 %)	n = 2 (1 %)	n = 12 (8 %)
Male, <i>n</i> (%)	86 (56%)	39 (67 %)	30 (48 %)	10 (53 %)	1 (50 %)	6 (50 %)
Age in years, <i>median (IQR)</i>	4 (1 – 7)	4 (2 – 7)	2.5 (1 – 5)	3 (0 – 6)	9.5 (2 - 17)	3.5 (0.5 – 8.5)
Viral co-infection, <i>n</i> (%)	71 (46 %)	18 (31 %)	37 (60 %)	14 (74 %)	0 (0 %)	2 (17 %)
RSV, <i>n</i> (%)	21 (14 %)	2 (3 %)	10 (16 %)	8 (41 %)	0 (0 %)	1 (8 %)
Influenza A/B, <i>n</i> (%)	29 (19 %)	12 (21 %)	14 (23 %)	3 (16 %)	0 (0 %)	0 (0 %)
SARS-CoV-2, <i>n</i> (%)	3 (2 %)	1 (2 %)	2 (3 %)	0 (0 %)	0 (0 %)	0 (0 %)
Other, <i>n</i> (%)	24 (16 %)	4 (7 %)	17 (27 %)	3 (16 %)	0 (0 %)	1 (8 %)
Bacterial co-infection with <i>H. influenzae</i> , <i>n</i> (%)	12 (8 %)	1 (2 %)	10 (16 %)	-	0 (0 %)	1 (8 %)
Clinical presentation						
Sepsis, SIRS, Toxic Shock, <i>n</i> (%)	28 (18 %)	18 (31 %)	1 (2 %)	1 (5 %)	1 (50 %)	7 (58 %)
ENT infections w/o cerebral invasion, <i>n</i> (%)	22 (14 %)	16 (28 %)	3 (5 %)	2 (11 %)	0 (0 %)	3 (25 %)
ENT infections w/ cerebral invasion, <i>n</i> (%)	15 (5 %)	9 (2 %)	6 (10 %)	0 (0 %)	0 (0 %)	0 (0 %)
CNS infection, <i>n</i> (%)	15 (10 %)	5 (9 %)	4 (7 %)	0 (0 %)	2 (100 %)	4 (33 %)
Pneumonia, <i>n</i> (%)	91 (59 %)	22 (38 %)	51 (82 %)	15 (79 %)	0 (0 %)	3 (25 %)
Skin and soft tissue infections, <i>n</i> (%)	22 (14 %)	17 (29 %)	4 (7 %)	0 (0 %)	0 (0 %)	1 (8 %)
Other infections, <i>n</i> (%)	5 (3 %)	2 (3 %)	0 (0 %)	1 (5 %)	0 (0 %)	3 (25 %)
Treatment						
Resuscitation, <i>n</i> (%)	6 (4 %)	5 (9 %)	0 (0 %)	1 (5 %)	0 (0 %)	0 (0 %)
PICU admission, <i>n</i> (%)	90 (59 %)	29 (50 %)	42 (68 %)	12 (63 %)	2 (100 %)	4 (33 %)
Invasive ventilation, <i>n</i> (%)	67 (44 %)	23 (40 %)	28 (45 %)	12 (63 %)	1 (50 %)	3 (25 %)
Administration of vasopressors/inotropes, <i>n</i> (%)	26 (17 %)	14 (24 %)	7 (11 %)	5 (26 %)	0 (0 %)	0 (0 %)
Extracorporeal membrane oxygenation, <i>n</i> (%)	1 (1 %)	1 (2 %)	0 (0 %)	0 (0 %)	0 (0 %)	0 (0 %)
Surgical source control, <i>n</i> (%)	41 (27 %)	22 (38 %)	14 (23 %)	0 (0 %)	0 (0 %)	7 (58 %)
Length of hospital stay hospital, <i>median (IQR)</i>	10 (5 – 19)	8 (4 – 19)	11 (5 – 19)	5 (4 – 6)	6 (1 - 11)	13 (7.5 – 25.5)
Discharge to rehabilitation/care facility, <i>n</i> (%)	5 (3 %)	2 (3 %)	2 (3 %)	0 (0%)	0 (0%)	1 (8 %)
PCPC at hospital discharge, <i>median (IQR)</i>	1 (1 – 2)	1 (1 – 2)	1 (1 – 2)	1 (1 – 2)	1 (1 – 1)	1 (1 – 2)
Deceased, <i>n</i> (%)	8 (5 %)	5 (9 %)	2 (3 %)	1 (5 %)	0 (0 %)	0 (0 %)

*Streptococcal species other than *S. pyogenes* and *S. pneumoniae*, IQR = interquartile range; ENT = ears nose and throat; CNS = central nervous system; SIRS = systemic inflammatory response syndrome, PICU = pediatric intensive care unit; PCPC = Pediatric Cerebral Performance Category

Table 3: National surveillance and multicentre study detection of pediatric severe and invasive bacterial infections between October 1st and December 31st of 2022 in North-Rhine Westphalia (Germany)

Pathogen	Detection by			Estimated number of non-captured cases	Estimated total number of cases
	NRL	MC	NRC + MC		
	N	n	n	n (95 % CI)	n
<i>S. pyogenes</i>	18	58	5	138 (48 – 400)	214
<i>S. pneumoniae</i>	18	63	5	151 (52 – 437)	232
<i>N. meningitidis</i>	6	2	2	0 (0 – 0)*	6
<i>H. influenzae</i>	6	31**	2	58 (10 – 329)	95

NRL = National reference laboratory, MC = multicentre study, *exact estimate: 2.1E-11 (9.4E-12 – 4.6E-11), **primary and co-infections included

Table 4: Expected and observed number of deaths in children < 15 years in Germany categorized by pathogen

Pathogen	Expected number of deaths in Germany per year*	Expected number of deaths in NRW per year*	Observed number of deaths in multicentre study in last quarter of 2022
Streptococci (all species)	4	0.9	7
<i>N. meningitidis</i>	8	1.8	0
<i>H. influenzae</i>	0.3	0.1	0

*based on national death cause statistics 2016 – 2019

Figure legends

Figure 1. Hospital-treated community-acquired bacterial infections in children in North Rhine-Westphalia in the last quarter of 2022

a) Clinical presentation

b) Treatment and outcomes

SIRS = systemic inflammatory response syndrome; TSS = toxic shock syndrome, ENT = ear-nose-throat; CNS = central nervous system; ICU = intensive care unit; CPR = cardiopulmonary resuscitation

Figure 2. Hospitalizations for community-acquired bacterial infections

a) *S. pyogenes*

b) *S. pneumoniae*

c) *N. meningitidis*

d) *H. influenzae*

Red solid line: incidence rates January 2020 - March 2023; black dashed line and grey band: average monthly incidence rates 2016 - 2019 with 95 % CI; green band: period of MC study

Figure 3. Hospitalizations due to acquired-bacterial infections from *S. pyogenes*, *S. pneumoniae*, *N. meningitidis*, and *H. influenzae*, January 2020 - March 2023

a) Cumulative hospitalization rates of *S. pneumoniae* (dark grey), *S. pyogenes* (medium grey), and *N. meningitidis* + *H. influenzae* (light grey)

b) IRRs of infections, reference period 2016 – 2019

Green band: period of MC study

Figure S1. Monthly incidence rate ratios of invasive bacterial infections in children in North Rhine-Westphalia January 2020 - March 2023 (reference period 2016 – 2019)

a) *S. pyogenes*

b) *S. pneumoniae*

c) *N. meningitidis*

d) *H. influenzae*







